Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-French health body approves AstraZeneca COVID-19 vaccine

Tue, 02nd Feb 2021 16:53

* Recommends use for those only aged under 65

* Decision makes AZ's vaccine third shot available in the
country
(Adds quote, details)

By Sudip Kar-Gupta and Geert De Clercq

PARIS, Feb 2 (Reuters) - France's top health advisory body
on Tuesday approved the use of AstraZeneca's COVID-19
vaccine, but said the shot should only be administered to those
aged under 65.

The Haute Autorite de la Sante (HAS) said people aged 50 to
65 with health issues and medical staff should get priority
access.

The decision makes AstraZeneca's vaccine the third shot
available in France, after those of Pfizer/BioNTech
and Moderna.

Its recommended use for those aged below 65 echoes similar
advice from experts in Italy, Austria, and Germany, which said
the vaccine should not be given to the elderly, citing a lack of
sufficient data to recommend use in older age groups.

"There is still insufficient data for those aged 65+. We
hope to have them in the coming weeks," the head of the HAS,
Dominique Le Guludec, told reporters.

"The vaccine's performance is satisfactory with a 62%-70%
efficacy depending on various study outcomes", she added.

The European Medicines Agency (EMA) gave the green light to
the AstraZeneca vaccine four days ago, saying there was not yet
enough results for people over the age of 55 to determine how
well the vaccine worked in that group but that it could still be
given to older people.

The approval is expected to ease pressure on the French
government, whose vaccination rollout strategy has been heavily
criticized for being too slow.

As of Feb. 1, more than 1.6 million doses had been
administered in France. That compares with an estimate of nearly
10 million in Britain.

But the European Union, which last year agreed to buy up to
400 million doses of the vaccine for the bloc, is at the centre
of a dispute with AstraZeneca over the speed of supplies.

Last week, the company unexpectedly announced cuts of up to
60% in supplies to European countries, citing production
problems at a Belgian factory and triggering a furious response
from Brussels.

The HAS said it expected France to get 10 million doses of
the AstraZeneca vaccine in the next three months, which would
allow 5 million people to get vaccinated, given its two-dose
regimen.

In the same timeframe, France hopes to secure 19.3 million
shots from Pfizer/BioNTech and 3 million from Moderna.

French European Affairs Minister Clement Beaune said on
Monday he expected first doses of the AstraZeneca vaccine to
arrive by next week at the latest.

(Reporting by Sudip Kar-Gupta, Geert De Clercq; Writing by
Matthias Blamont; Editing by Bernadette Baum and Rosalba
O'Brien)

More News
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.